Wonder why MNTA didn't PR this.
Sentiment: Strong Buy
Looks like The date came and went . No word from the company or the
FDA. Looks like the company is left in a void . TEVA patent expiration 2015-which still does not mater until or if the FDA ever gives a thumbs up.
Yes it was a good find. But with them doing their own trials this will suck a lot of cash going forward with no promise of a approved drug. The lack of clarity this company has continually refused to have on any FDA approval of their generic Copaxone, and continued insider sales(albeit small) still raise doubt that this can be a long lived company, unless they think about dilution and a share offering the May dates have come and gone ,and the FDA after 6 years has not given any approval.
Careful reading of the page shows the following statement "Not FDA Approved for Orphan Indication". What gives?
duude!... there is a distinction between "Designated" and "Approved"... one implies the beginning of clinical trials and the other the end... designated, necuparanib will qualify for incentives from the FDA as it goes to trials... aloha K
New presentation tomorrow , bet it sounds the same a always. We are in discussions but to no good conclusion and or approval. hurry up and wait, oh and we are running low on cash and will do a secondary offering.
Listened to the Wells Fargo conference call- Not impressed. pass on further positioning till much later date this year.The big question is FDA approval, the patents still expire in 2015. Also see FDA approval difficulties for their bio-similar products down the road( many years from anda submission to approval-following time horizon from this copaxone fiasco).
Do you mean they hinted a further delay for generic Copaxone approval ? How much delay are they expecting ? What's the reason for the delay ?
Listen to the call. That being said- talked about giving gene info to FDA recently and the review of that info going forward as a possible delay for any/ IF at all approval.
wasssup ding!.... i think risk is relative and not necessarily bad... people buy lotto with a much higher lower chance of reward... I call that crazily risky... but if given the chance I would buy a couple... thankfully we live in a place where it is illegal... unlike the lotto where your ticket becomes worthless at a certain day, biotech like momenta gives you a chance to recoup if it goes down... there's too much good science in this company that it would just disappear overnight... but if they'll hit their stride, look out... it will reward you plenty... not as much as a lotto ticket but for me, enough to buy rice to cook for dinner... aloha K
Zacks' bottom line was "Hold" (rating 3). This is better than sell (rating 4), but it is not as high as buy (rating 2) or strong buy (rating 1). So, what was it about "hold" that seems right?
Zacks' text was not consistent with the "hold" rating. I find that articles that are internally inconsistent are lacking in credibility.
The problem with most agency ratings is that they are based on past stock price movements. We want to look past these for companies that are undergoing radical changes, such as Momenta.
"So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future" - i believe that's the part they got right. Why didn't they rate it a "buy" at this price? I have no clue. And, yes, that's inconsistent. I suppose they will rate it a buy "after" the stock doubles on good news. Anyhow, I'm not waiting - I'm buying.....GLTA